within Pharmacolibrary.Drugs.ATC.A;

model A02BD11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.69,
    Cl             = 0.2,
    adminDuration  = 600,
    adminMass      = 2.0,
    adminCount     = 1,
    Vd             = 0.018,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>A fixed-combination regimen used in eradication of Helicobacter pylori infection. It contains pantoprazole (proton pump inhibitor), amoxicillin (penicillin-antibiotic), clarithromycin (macrolide-antibiotic), and metronidazole (nitroimidazole-antibiotic). These are combined to suppress gastric acid and provide broad-spectrum antibacterial action. The combination is used as first-line therapy in several clinical guidelines.</p><h4>Pharmacokinetics</h4><p>No experimental pharmacokinetic (PK) model for the fixed four-drug combination was identified; parameters herein are estimated based on representative oral PK profiles from literature for each drug in healthy adults.</p><h4>References</h4><ol><li><p>Cheer, SM, et al., &amp; Lamb, HM (2003). Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. <i>Drugs</i> 63(1) 101â€“133. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200363010-00006&quot;>10.2165/00003495-200363010-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12487624/&quot;>https://pubmed.ncbi.nlm.nih.gov/12487624</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A02BD11;
